Targeting HIV latency: resting memory T cells, hematopoietic progenitor cells and future directions

Expert Rev Anti Infect Ther. 2014 Oct;12(10):1187-201. doi: 10.1586/14787210.2014.956094. Epub 2014 Sep 4.

Abstract

Current therapy for HIV effectively suppresses viral replication and prolongs life, but the infection persists due, at least in part, to latent infection of long-lived cells. One favored strategy toward a cure targets latent virus in resting memory CD4(+) T cells by stimulating viral production. However, the existence of an additional reservoir in bone marrow hematopoietic progenitor cells has been detected in some treated HIV-infected people. This review describes approaches investigators have used to reactivate latent proviral genomes in resting CD4(+) T cells and hematopoietic progenitor cells. In addition, the authors review approaches for clearance of these reservoirs along with other important topics related to HIV eradication.

Keywords: HDAC inhibitors; HIV latency; HIV/AIDS; antiviral therapy; hematopoietic progenitor cells; resting memory CD4+ T cells.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • CD4-Positive T-Lymphocytes / immunology
  • CD4-Positive T-Lymphocytes / virology*
  • HIV / drug effects
  • HIV / immunology
  • HIV / physiology*
  • HIV Infections / drug therapy*
  • HIV Infections / immunology
  • HIV Infections / virology
  • Hematopoietic Stem Cells / immunology*
  • Humans
  • Immunologic Memory*
  • Models, Immunological
  • Virus Latency
  • Virus Replication / drug effects